10.39
-1.63 (-13.56%)
| Previous Close | 12.02 |
| Open | 11.24 |
| Volume | 5,313,867 |
| Avg. Volume (3M) | 2,702,160 |
| Market Cap | 1,058,211,136 |
| Price / Sales | 22.73 |
| Price / Book | 1.08 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Operating Margin (TTM) | -1,588.96% |
| Diluted EPS (TTM) | -5.45 |
| Quarterly Revenue Growth (YOY) | -24.00% |
| Total Debt/Equity (MRQ) | 10.56% |
| Current Ratio (MRQ) | 6.73 |
| Operating Cash Flow (TTM) | -356.74 M |
| Levered Free Cash Flow (TTM) | -184.96 M |
| Return on Assets (TTM) | -27.81% |
| Return on Equity (TTM) | -52.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Intellia Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -2.5 |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.40 |
|
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.19% |
| % Held by Institutions | 92.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Casdin Capital, Llc | 30 Sep 2024 | 2,000,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 91.00 (Chardan Capital, 775.84%) | Buy |
| Median | 45.00 (333.11%) | |
| Low | 12.00 (Goldman Sachs, 15.50%) | Hold |
| Average | 44.90 (332.15%) | |
| Total | 6 Buy, 4 Hold | |
| Avg. Price @ Call | 13.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 14 Jan 2025 | 12.00 (15.50%) | Hold | 9.70 |
| 25 Oct 2024 | 20.00 (92.49%) | Hold | 15.95 | |
| Oppenheimer | 13 Jan 2025 | 40.00 (284.99%) | Buy | 9.70 |
| 11 Nov 2024 | 60.00 (477.48%) | Buy | 17.50 | |
| BMO Capital | 10 Jan 2025 | 50.00 (381.23%) | Buy | 10.20 |
| Wells Fargo | 10 Jan 2025 | 60.00 (477.48%) | Buy | 10.20 |
| 18 Nov 2024 | 70.00 (573.72%) | Buy | 14.17 | |
| Canaccord Genuity | 19 Nov 2024 | 90.00 (766.22%) | Buy | 14.13 |
| Chardan Capital | 18 Nov 2024 | 91.00 (775.84%) | Buy | 14.17 |
| 24 Oct 2024 | 88.00 (746.97%) | Buy | 15.85 | |
| Wedbush | 18 Nov 2024 | 14.00 (34.74%) | Hold | 14.17 |
| Barclays | 08 Nov 2024 | 55.00 (429.36%) | Buy | 16.73 |
| Baird | 25 Oct 2024 | 18.00 (73.24%) | Hold | 15.95 |
| Citigroup | 25 Oct 2024 | 19.00 (82.87%) | Hold | 15.95 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BASTA JAMES | - | 12.13 | -7,074 | -85,808 |
| CLARK ELIANA | - | 12.18 | -7,978 | -96,823 |
| DUBE MICHAEL P | - | 12.13 | -1,372 | -16,642 |
| HICKS DEREK | - | 12.13 | -6,502 | -78,869 |
| LEBWOHL DAVID | - | 12.13 | -9,557 | -115,926 |
| LEONARD JOHN M | - | 12.13 | -26,807 | -325,169 |
| SEPP-LORENZINO LAURA | - | 12.13 | -8,966 | -108,758 |
| Aggregate Net Quantity | -68,256 | |||
| Aggregate Net Value ($) | -827,995 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 12.14 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CLARK ELIANA | Officer | 03 Jan 2025 | Sell (-) | 7,422 | 12.13 | 90,029 |
| SEPP-LORENZINO LAURA | Officer | 03 Jan 2025 | Sell (-) | 8,966 | 12.13 | 108,758 |
| LEONARD JOHN M | Officer | 03 Jan 2025 | Sell (-) | 26,807 | 12.13 | 325,169 |
| LEBWOHL DAVID | Officer | 03 Jan 2025 | Sell (-) | 9,557 | 12.13 | 115,926 |
| HICKS DEREK | Officer | 03 Jan 2025 | Sell (-) | 6,502 | 12.13 | 78,869 |
| BASTA JAMES | Officer | 03 Jan 2025 | Sell (-) | 7,074 | 12.13 | 85,808 |
| DUBE MICHAEL P | Officer | 03 Jan 2025 | Sell (-) | 1,372 | 12.13 | 16,642 |
| CLARK ELIANA | Officer | 02 Jan 2025 | Sell (-) | 556 | 12.22 | 6,794 |
| SEPP-LORENZINO LAURA | Officer | 01 Jan 2025 | Option execute | 3,500 | - | - |
| LEBWOHL DAVID | Officer | 01 Jan 2025 | Option execute | 3,189 | - | - |
| LEONARD JOHN M | Officer | 01 Jan 2025 | Option execute | 7,850 | - | - |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |